Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| Gene | FLT3 |
| Variant | D835delinsLK |
| Impact List | indel |
| Protein Effect | unknown |
| Gene Variant Descriptions | FLT3 D835delinsLK results in the deletion of aspartic acid (D) at amino acid 835 in the protein kinase domain of the Flt3 protein, combined with the insertion of a leucine (L) and a lysine (K) at the same site (UniProt.org). D835delinsLK has been identified in the scientific literature (PMID: 40196870), but has not been biochemically characterized and therefore, its effect on Flt3 protein function is unknown (PubMed, Sep 2025). |
| Associated Drug Resistance | |
| Category Variants Paths |
FLT3 mutant FLT3 exon20 FLT3 D835delinsLK |
| Transcript | NM_004119.3 |
| gDNA | chr13:g.28018503_28018505delinsCTTAAG |
| cDNA | c.2503_2505delinsCTTAAG |
| Protein | p.D835delinsLK |
| Source Database | RefSeq |
| Genome Build | GRCh38/hg38 |
| Transcript | gDNA | cDNA | Protein | Source Database | Genome Build |
|---|---|---|---|---|---|
| NM_004119.3 | chr13:g.28018503_28018505delinsCTTAAG | c.2503_2505delinsCTTAAG | p.D835delinsLK | RefSeq | GRCh38/hg38 |
| Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
|---|---|---|---|---|---|---|---|
| FLT3 D835delinsLK | hematologic cancer | sensitive | Gilteritinib | Preclinical | Actionable | In a preclinical study, Xospata (gilteritinib) treatment inhibited Flt3 signaling and viability in a cell line expressing FLT3 D835delinsLK in culture and inhibited growth in a transplant model (PMID: 40196870). | 40196870 |
| FLT3 D835delinsLK | hematologic cancer | decreased response | Quizartinib | Preclinical | Actionable | In a preclinical study, cells expressing FLT3 D835delinsLK were less sensitive to Vanflyta (quizartinib) compared to cells expressing a FLT3-ITD in culture and in a transplant model (PMID: 40196870). | 40196870 |
| FLT3 D835delinsLK | hematologic cancer | sensitive | Midostaurin | Preclinical - Cell culture | Actionable | In a preclinical study, Rydapt (midostaurin) treatment decreased viability in a cell line expressing FLT3 D835delinsLK in culture (PMID: 40196870). | 40196870 |